William Pickering
Stock Analyst at Bernstein
(3.02)
# 2,897
Out of 4,371 analysts
216
Total ratings
53.6%
Success rate
3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Rated: Hold | $35 → $46 | $74.89 | -38.58% | 9 | May 13, 2026 | |
| NTLA Intellia Therapeutics | Rated: Hold | $13 → $17 | $13.40 | +26.87% | 14 | May 13, 2026 | |
| CRSP CRISPR Therapeutics AG | Rated: Hold | $50 → $56 | $52.80 | +6.06% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Rated: Buy | $40 → $39 | $29.73 | +31.18% | 18 | May 13, 2026 | |
| DYN Dyne Therapeutics | Rated: Hold | $23 → $24 | $18.31 | +31.08% | 7 | May 13, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $100 → $114 | $68.92 | +65.42% | 4 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $94 → $82 | $57.43 | +42.78% | 21 | May 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $577 → $572 | $448.11 | +27.65% | 30 | May 5, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $451 → $447 | $304.64 | +46.73% | 20 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Hold | $3.85 | $1.94 | +98.97% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $916 → $921 | $635.58 | +44.91% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 | $16.07 | +24.46% | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 | $32.46 | -13.74% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $29.54 | +18.50% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $157 → $201 | $199.99 | +0.51% | 10 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $89 | $75.39 | +18.05% | 22 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 → $9 | $11.15 | -19.28% | 12 | Nov 6, 2025 |
Arrowhead Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $35 → $46
Current: $74.89
Upside: -38.58%
Intellia Therapeutics
May 13, 2026
Rated: Hold
Price Target: $13 → $17
Current: $13.40
Upside: +26.87%
CRISPR Therapeutics AG
May 13, 2026
Rated: Hold
Price Target: $50 → $56
Current: $52.80
Upside: +6.06%
Beam Therapeutics
May 13, 2026
Rated: Buy
Price Target: $40 → $39
Current: $29.73
Upside: +31.18%
Dyne Therapeutics
May 13, 2026
Rated: Hold
Price Target: $23 → $24
Current: $18.31
Upside: +31.08%
BridgeBio Pharma
May 8, 2026
Reiterated: Buy
Price Target: $100 → $114
Current: $68.92
Upside: +65.42%
BioMarin Pharmaceutical
May 5, 2026
Rated: Buy
Price Target: $94 → $82
Current: $57.43
Upside: +42.78%
Vertex Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $577 → $572
Current: $448.11
Upside: +27.65%
Alnylam Pharmaceuticals
May 1, 2026
Reiterated: Buy
Price Target: $451 → $447
Current: $304.64
Upside: +46.73%
Allogene Therapeutics
Apr 14, 2026
Maintained: Hold
Price Target: $3.85
Current: $1.94
Upside: +98.97%
Apr 8, 2026
Maintained: Buy
Price Target: $916 → $921
Current: $635.58
Upside: +44.91%
Mar 25, 2026
Maintained: Hold
Price Target: $20
Current: $16.07
Upside: +24.46%
Mar 20, 2026
Initiated Coverage: Hold
Price Target: $28
Current: $32.46
Upside: -13.74%
Mar 20, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $29.54
Upside: +18.50%
Feb 6, 2026
Maintained: Hold
Price Target: $157 → $201
Current: $199.99
Upside: +0.51%
Jan 13, 2026
Maintained: Hold
Price Target: $65 → $89
Current: $75.39
Upside: +18.05%
Nov 6, 2025
Downgraded: Hold
Price Target: $34 → $9
Current: $11.15
Upside: -19.28%